Search results for ''

Clinical studies

Vonafexor is currently in Phase 2 clinical studies

• Phase 2 in CKD and suspected MASH: Vonafexor in patients with impaired renal function and suspected Metabolic Dysfunction-associated Steatohepatitis (MASH) Learn more about the clinical study
• Phase 2 ALPESTRIA-1 in Alport syndrome: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome. Learn more about ALPESTRIA-1 study

Vonafexor is already supported by 9 clinical studies

• Phase 2a LIVIFY study: Safety,

Read more »

Published on 11/05/2023

Pipeline

ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function as CKD, Alport syndrome, NASH and DKD.

Published on 11/05/2023

Science

Read more »

Published on 11/05/2023

Vonafexor series

ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function like Alport syndrome, CKD and MASH*.

Vonafexor (EYP001)

Vonafexor is a synthetic non-steroidal, non-bile acid farnesoid X receptor (FXR)** agonist. It activates FXR with a high selectivity compared to other nuclear receptors and does not display any activity on bile acid receptor TGR5.
This small molecule has a different structure compared to other FXR agonists and induces a differential set of target genes based on ligand binding patterns.

Read more »

Published on 11/05/2023

5th CKD Summit – Chronic Kidney Disease Drug Development

7-9 March, 2023
Boston, MA

ENYO was attending the 5th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.

https://ckd3-summit.com/

Read more »

Published on 07/03/2023